Liraglutide Heals Diabetic Wounds by Activating a New Cellular Repair Pathway
Liraglutide accelerated diabetic wound healing in mice by directly binding to the Myo1c protein and activating the Myo1c/Dock5 pathway that promotes skin cell proliferation, migration, and adhesion.
Quick Facts
What This Study Found
Liraglutide directly binds Myo1c at arginine 93, enhances Myo1c/Dock5 interaction to promote keratinocyte proliferation, migration, and adhesion. Dock5 keratinocyte-specific knockout abolished liraglutide wound-healing benefits.
Key Numbers
Liraglutide significantly accelerated wound closure in both db/db and STZ-induced diabetic mouse models.
How They Did This
Wound healing studies in db/db and STZ-induced diabetic mice with liraglutide treatment. Dock5 keratinocyte-specific knockout mice to confirm mechanism. Characterized re-epithelialization, collagen deposition, ECM remodeling, and keratinocyte functions. Identified Myo1c binding site and Dock5 pathway.
Why This Research Matters
Diabetic foot ulcers lead to over 100,000 amputations per year in the US alone. Liraglutide is already FDA-approved and widely used — discovering that it promotes wound healing through a distinct pathway beyond blood sugar control could immediately expand its clinical applications.
The Bigger Picture
GLP-1 drugs continue to reveal unexpected therapeutic effects beyond blood sugar and weight. This study identifies a completely new mechanism — direct protein binding rather than receptor signaling — through which liraglutide promotes tissue repair. If validated in humans, it could transform diabetic wound care and potentially expand to other tissue repair applications.
What This Study Doesn't Tell Us
Mouse wound models differ from human diabetic ulcers in size, healing dynamics, and microenvironment. The optimal dosing route (systemic vs topical) for wound healing is unclear. Human clinical trials are needed. The mechanism involves a non-GLP-1R pathway, which may behave differently across species.
Questions This Raises
- ?Would topical application of liraglutide directly on diabetic wounds be effective, or is systemic dosing required?
- ?Do patients already taking liraglutide for diabetes show improved wound healing outcomes in clinical records?
- ?Could this Myo1c/Dock5 pathway be targeted more specifically to develop dedicated wound-healing drugs?
Trust & Context
- Key Stat:
- New healing pathway Liraglutide directly binds Myo1c protein to activate wound repair — a completely different mechanism from its blood sugar-lowering action
- Evidence Grade:
- Moderate evidence: published in Advanced Science with thorough mechanistic investigation using knockout mice and two diabetic models, but no human wound healing data yet.
- Study Age:
- Published in 2024 in Advanced Science. Reveals a novel non-receptor mechanism for GLP-1 drug action.
- Original Title:
- Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.
- Published In:
- Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(39), e2405987 (2024)
- Authors:
- Zhang, Qian(4), Zhang, Chunlin, Kang, Changjiang, Zhu, Jiaran, He, Qingshan, Li, Hongwei, Tong, Qiang, Wang, Min, Zhang, Linlin, Xiong, Xin, Wang, Yuren, Qu, Hua, Zheng, Hongting, Zheng, Yi
- Database ID:
- RPEP-09649
Evidence Hierarchy
Frequently Asked Questions
Can liraglutide help diabetic wounds heal faster?
In this mouse study, liraglutide significantly accelerated diabetic wound healing by activating a skin cell repair pathway. While promising, human clinical trials are needed before it can be recommended for wound care. Patients already on liraglutide for diabetes may be receiving a hidden wound-healing benefit.
How does liraglutide promote wound healing?
Liraglutide directly binds to a motor protein called Myo1c in skin cells, which activates Dock5 and promotes the proliferation, migration, and adhesion of keratinocytes — all essential processes for closing wounds. This is a completely different mechanism from how it lowers blood sugar.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09649APA
Zhang, Qian; Zhang, Chunlin; Kang, Changjiang; Zhu, Jiaran; He, Qingshan; Li, Hongwei; Tong, Qiang; Wang, Min; Zhang, Linlin; Xiong, Xin; Wang, Yuren; Qu, Hua; Zheng, Hongting; Zheng, Yi. (2024). Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(39), e2405987. https://doi.org/10.1002/advs.202405987
MLA
Zhang, Qian, et al. "Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.." Advanced science (Weinheim, 2024. https://doi.org/10.1002/advs.202405987
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5." RPEP-09649. Retrieved from https://rethinkpeptides.com/research/zhang-2024-liraglutide-promotes-diabetic-wound
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.